FTC asks ap­peals court to re­verse de­ci­sion in po­ten­tial an­titrust case against Ab­b­Vie, gener­ic man­u­fac­tur­ers

The FTC wants an ap­peals court to re­verse a dis­trict court’s de­ci­sion to dis­miss a case against Ab­b­Vie’s For­est Lab­o­ra­to­ries and gener­ic drug man­u­fac­tur­ers over pos­si­ble an­titrust vi­o­la­tions with its high blood pres­sure drug Bystolic (nebivolol).

In a 2020 class ac­tion law­suit, CVS, Rite Aid and oth­er re­tail­ers ac­cused Al­ler­gan (which ac­quired For­est in 2014 be­fore it was lat­er bought by Ab­b­Vie), and gener­ic gi­ants like Tor­rent and Ameri­gen of a re­verse pay­ment scheme, al­so known as pay-for-de­lay deal, where­by a brand-name man­u­fac­tur­er pays gener­ic com­pa­nies to not make gener­ics of the drug avail­able in ex­change for a cer­tain amount of time and in ex­change for mon­ey.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER